Premium
IC‐P‐109: RATIONALE AND DESIGN OF THE NL‐ENIGMA STUDY: A DUTCH 24‐WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE
Author(s) -
Scheltens Nienke M.E.,
Berckel Bart N.M.,
Boellaard Ronald,
Barkhof Frederik,
Van der Flier Wiesje M.,
Kamphuis Patrick,
Scheltens Philip
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.115
Subject(s) - dementia , positron emission tomography , medicine , neuroimaging , magnetic resonance imaging , default mode network , synapse , alzheimer's disease , standardized uptake value , neuroscience , disease , psychology , cognition , psychiatry , radiology
Prodromal AD subjects demonstrated greater brain atrophy at 1 year compared with biomarker-negative observational cohort subjects. Avagacestat-treated subjects exhibited greater volume loss than did placebo subjects, a seemingly paradoxical result similar to findings previously reported with other amyloid-lowering treatments such as AN1792 (Fox et al, Neurology 2005) or bapineuzumab (pooled analysis, Fox et al, CTAD 2012).